A large unilateral basal cell carcinoma treated with Hedgehog inhibitor sonidegib: a case report

• Päätekijät: Maria Alessandra Mattioli (Tekijä), Valentina Benzecry (Tekijä), Giulia Murgia (Tekijä), Nerina Denaro (Tekijä), Angelo Valerio Marzano (Tekijä), Emanuela Passoni (Tekijä), Gianluca Nazzaro (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: PAGEPress Publications, 2024-11-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Yhteenveto

Basal cell carcinoma (BCC) is the most common non-melanoma skin cancer. BCCs are categorized into "easy-to-treat" and "difficult-to-treat" groups, with the latter including all BCCs that are challenging to manage due to technical, patient-related, or tumor-related factors, such as locally advanced BCCs. In this report, we describe an 84-year-old patient with an extensive, unilateral BCC. Following a decision by the multidisciplinary skin cancer board, the patient was successfully treated with a daily dose of 200 mg of sonidegib, an inhibitor of the Hedgehog pathway, for eight months, acquiring complete clinical and histopathological remission. No significant side effects were reported. The follow-up period of 24 months has shown no negative results.

Huomautukset

10.4081/dr.2024.10152
2036-7392
2036-7406